Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2016-05-17 Board/Management Inform…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Retirement of Non-Executive Director 2 pages 240.0KB
Board/Management Information Classification · 100% confidence The document announces the retirement of a Non-Executive Director and changes in board committee roles. It specifically mentions the withdrawal of a resolution related to the re-election of the retiring director at the AGM. There is no financial data, no report attached or referenced as being published, and no mention of earnings or regulatory filings. The content is focused on board/management changes, which fits the category of Board/Management Information (MANG). The document length is short and the content is clearly about management changes rather than a report or announcement of a report.
2016-05-17 English
Phosphagenics Expands Japanese Option to Oxycodone Patch 2 pages 245.1KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Phosphagenics Limited about signing a Japanese license option agreement for a drug patch product. It discusses the terms of the licensing option, potential payments, and collaboration plans. There are no financial statements, regulatory certifications, or detailed financial data. The content is an update on a capital/licensing agreement rather than a full financial report or earnings release. It fits best under Capital/Financing Update (CAP) as it relates to licensing and potential revenue-generating agreements.
2016-05-16 English
Ceasing to be a substantial holder 2 pages 121.1KB
Regulatory Filings Classification · 90% confidence The document contains only references to omitted pictures and no textual content or financial data. It is extremely short (223 characters) and does not contain any report, announcement, or detailed information. Given the lack of content, it cannot be classified as a substantive report or announcement. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without specific content.
2016-05-02 English
Phosphagenics Signs Japanese License Option and R&D Alliance 2 pages 77.2KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new license option agreement and R&D alliance between Phosphagenics Limited and a Japanese healthcare company. It details the terms of the agreement, potential payments, and development plans. There is no financial data, no regulatory filing references, no voting results, no management or board changes, no earnings data, and no mention of a report being attached or published. The content focuses on a strategic partnership and licensing deal, which fits the category of Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes through licensing and alliance agreements.
2016-04-28 English
2015 Annual Report 80 pages 4.5MB
Regulatory Filings
2016-04-14 English
Notice of Annual General Meeting and Proxy Form 13 pages 1.3MB
AGM Information Classification · 95% confidence The document is an invitation and notice for the Annual General Meeting (AGM) of Phosphagenics Limited, scheduled for 19 May 2016. It includes details about the meeting agenda, including the consideration of the Annual Report for the year ended 31 December 2015, election and re-election of directors, adoption of the Remuneration Report, proxy voting instructions, and shareholder questions. The text is primarily focused on informing shareholders about the AGM logistics, resolutions to be voted on, and procedural information rather than presenting the full Annual Report or financial statements themselves. The document length is about 15,000 characters, which is substantial but the content is clearly a Notice of Meeting and related explanatory notes for the AGM. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices and explanatory notes. It is not the Annual Report itself (10-K), nor a report publication announcement (RPA), as it contains detailed meeting and voting information. Hence, the correct classification is AGM-R with high confidence.
2016-04-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.